AtaiBeckley and PsyPAN Win Silver in Patient Participant Index
Event summary
- AtaiBeckley and PsyPAN received the Silver Award in OVID Health's 2026 Patient Participant Index for their collaboration on participant-informed psychedelic research.
- The partnership includes a 12-month peer-support pilot program launched in 2025, funded by an unrestricted grant from AtaiBeckley.
- AtaiBeckley’s pipeline includes BPL-003 (Phase 3 planning), VLS-01 and EMP-01 (both Phase 2) for mental health treatments.
The big picture
AtaiBeckley’s Silver Award underscores the growing emphasis on participant-centric research in psychedelic medicine. The collaboration with PsyPAN reflects a broader industry shift toward ethical, transparent clinical development, particularly as novel mental health treatments near commercialization. With multiple programs in Phase 2 and 3, AtaiBeckley is positioning itself as a leader in integrating patient insights into drug development.
What we're watching
- Participant Engagement
- How AtaiBeckley will scale its participant-informed research model across international trials.
- Regulatory Alignment
- Whether the peer-support program model gains broader adoption in psychedelic clinical research.
- Pipeline Progress
- The pace at which AtaiBeckley advances BPL-003, VLS-01, and EMP-01 through late-stage trials.
Related topics